Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1173 studies found for:    "Slow Virus Diseases"
Show Display Options
Rank Status Study
1 Completed Feasibility of Measuring Immune Resp, Activation in Foreskin/Mucosa in HIV-, Uncircumcised High-HIV-risk MSM, Lima Peru
Conditions: HIV Infections;   Acquired Immunodeficiency Syndrome;   Lentivirus Infections;   Retroviridae Infections;   RNA Virus Infections;   Virus Diseases;   Sexually Transmitted Diseases, Viral;   Sexually Transmitted Diseases;   Immunologic Deficiency Syndromes;   Immune System Diseases;   Slow Virus Diseases
Interventions: Procedure: Circumcision;   Procedure: Flexible sigmoidoscopy
2 Enrolling by invitation mVIP (Use of mHealth Technology for Supporting Symptom Management in Underserved Persons Living With HIV)
Condition: HIV (Human Immunodeficiency Virus)
Interventions: Device: Health Management App with symptom strategies;   Device: My Fitness Pal App
3 Completed Retrospective Study of the Survival of Patients Suffering From Hiv-related Progressive Multifocal Leukoencephalopathy
Condition: Progressive Multifocal Leukoencephalopathy
Intervention:
4 Recruiting Relative Bioavailability Study of a Fixed-dose Combination Dolutegravir/Abacavir/Lamivudine Dispersible Tablet
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: DTG/ABC/3TC FDC DISPERSIBLE TABLET;   Drug: EPZICOM (ABC/3TC);   Drug: TIVICAY (DTG)
5 Not yet recruiting Feasibility of an Ingestible Sensor System to Measure PrEP Adherence in YMSM
Condition: Human Immunodeficiency Virus
Intervention: Device: Proteus Sensor System
6 Not yet recruiting Co-adaptation Between Human Immunodeficiency Virus (HIV) and Cluster of Differentiation 8 (CD8) Cellular Immunity
Condition: HIV Infection
Intervention: Other: Non interventional study
7 Not yet recruiting Maraviroc Efficacy for Hepatitis C
Conditions: Hepatitis C;   Human Immunodeficiency Virus
Intervention: Drug: Maraviroc
8 Recruiting New Strategies to Assess Anal Cancer Risk In Women
Conditions: Human Immunodeficiency Virus (HIV);   Human Papillomavirus (HPV)
Interventions: Procedure: Perianal and Digital Anorectal Exam;   Procedure: Cervical Swabs;   Procedure: Anal Swabs;   Procedure: High Resolution Anoscopy (HRA)
9 Not yet recruiting A Study of the Relative Bioavailability of BMS-626529 Administered as BMS-663068 (Prodrug) From 150mg Low-dose Extended-release Tablets Compared to 600mg Reference Extended-release Tablets in Healthy Subjects
Condition: HIV (Human Immuno-Deficiency Virus)
Interventions: Drug: BMS-663068 (1 tablet at 600 mg);   Drug: BMS-663068 (4 tablets at 150 mg each tablet)
10 Recruiting Trial to Assess the Continued Safety of and Adherence to a Vaginal Ring Containing Dapivirine in Women
Condition: Human Immunodeficiency Virus
Intervention: Device: Dapivirine Vaginal Ring
11 Recruiting Autonomic Neuropathy, GI Motility, and Inflammation in HIV
Condition: HIV Disease
Intervention: Drug: Pyridostigmine
12 Not yet recruiting Romidepsin Plus 3BNC117 Phase 2a Study
Condition: Human Immunodeficiency Virus (HIV)
Interventions: Drug: 3BNC117;   Drug: Romidepsin
13 Recruiting 'HI-4-TU' Study: Health Improvement for Teen Ugandans Study
Conditions: Pregnancy;   Human Immunodeficiency Virus;   Sexually Transmitted Diseases
Interventions: Behavioral: enhanced group support;   Behavioral: enhanced individual support
14 Recruiting An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 2)
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: Dolutegravir (DTG);   Drug: Lamivudine (3TC);   Drug: Tenofovir disoproxil fumarate/Emtricitabine (TDF/FTC FDC)
15 Recruiting An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: Dolutegravir (DTG);   Drug: Lamivudine (3TC);   Drug: Tenofovir disoproxil fumarate/Emtricitabine (TDF/FTC FDC)
16 Recruiting 3BNC117 and 10-1074 in HIV-infected Individuals
Condition: Human Immunodeficiency Virus (HIV)
Interventions: Drug: 3BNC117;   Drug: 10-1074;   Other: Analytical treatment interruption;   Drug: Placebo
17 Recruiting 3BNC117 and 10-1074 in HIV Uninfected Adults
Condition: Human Immunodeficiency Virus
Interventions: Drug: 3BNC117;   Drug: 10-1074;   Drug: Placebo
18 Recruiting Non-Invasive Oral Cancer Screening Among HIV Smokers
Conditions: Malignant Neoplasms of Mesothelial and Soft Tissue;   Human Immunodeficiency Virus
Interventions: Behavioral: Screening Interview;   Device: Carbon Monoxide Test;   Behavioral: Self-Help Materials;   Procedure: Visual Oral Screening Examination;   Procedure: Direct Fluorescent Oral Visualization Examination;   Procedure: Oral Biopsy
19 Recruiting Soy Modulation of Immune Activation, LDL- Levels, and Lowering Inflammation by Pretzel Isoflavone Dietary Intervention
Conditions: Human Immunodeficiency Virus (HIV) Infection;   Hypercholesterolemia
Interventions: Other: Soy Pretzel;   Other: Wheat Pretzel
20 Recruiting DTaP-IPV-HB-PRP-T Combined Vaccine as a Primary Series and a 2nd Year of Life Booster in HIV-Exposed Infected and Uninfected
Conditions: Diphtheria;   Tetanus;   Pertussis;   Hepatitis B;   Polio;   Human Immunodeficiency Virus Infection
Intervention: Biological: Hexaxim®: DTaP-IPV-HB-PRP-T Combined Vaccine

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years